126 related articles for article (PubMed ID: 36975114)
1. Intravitreal Topotecan 90 µg for Recurrent Solid Retinoblastoma Tumors Is Effective and Not Toxic.
Abramson DH; Francis JH
J Pediatr Ophthalmol Strabismus; 2023; 60(2):e16-e18. PubMed ID: 36975114
[TBL] [Abstract][Full Text] [Related]
2. Combined intravitreal melphalan and topotecan for refractory or recurrent vitreous seeding from retinoblastoma.
Ghassemi F; Shields CL; Ghadimi H; Khodabandeh A; Roohipoor R
JAMA Ophthalmol; 2014 Aug; 132(8):936-41. PubMed ID: 24789622
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of intravitreal topotecan dose levels, toxicity and efficacy for retinoblastoma vitreous seeds: a preclinical and clinical study.
Bogan CM; Kaczmarek JV; Pierce JM; Chen SC; Boyd KL; Calcutt MW; Bridges TM; Lindsley CW; Nadelmann JB; Liao A; Hsieh T; Abramson DH; Francis JH; Friedman DL; Richmond A; Daniels AB
Br J Ophthalmol; 2022 Feb; 106(2):288-296. PubMed ID: 33972235
[TBL] [Abstract][Full Text] [Related]
4. Intraocular Pressure Changes Following Intravitreal Melphalan and Topotecan for the Treatment of Retinoblastoma With Vitreous Seeding.
Karl MD; Francis JH; Iyer S; Marr B; Abramson DH
J Pediatr Ophthalmol Strabismus; 2017 May; 54(3):185-190. PubMed ID: 28092395
[TBL] [Abstract][Full Text] [Related]
5. Intravitreal HDAC Inhibitor Belinostat Effectively Eradicates Vitreous Seeds Without Retinal Toxicity In Vivo in a Rabbit Retinoblastoma Model.
Kaczmarek JV; Bogan CM; Pierce JM; Tao YK; Chen SC; Liu Q; Liu X; Boyd KL; Calcutt MW; Bridges TM; Lindsley CW; Friedman DL; Richmond A; Daniels AB
Invest Ophthalmol Vis Sci; 2021 Nov; 62(14):8. PubMed ID: 34757417
[TBL] [Abstract][Full Text] [Related]
6. Intravitreal melphalan for persistent or recurrent retinoblastoma vitreous seeds: preliminary results.
Shields CL; Manjandavida FP; Arepalli S; Kaliki S; Lally SE; Shields JA
JAMA Ophthalmol; 2014 Mar; 132(3):319-25. PubMed ID: 24407202
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and Toxicity of Intravitreous Chemotherapy for Retinoblastoma: Four-Year Experience.
Francis JH; Brodie SE; Marr B; Zabor EC; Mondesire-Crump I; Abramson DH
Ophthalmology; 2017 Apr; 124(4):488-495. PubMed ID: 28089679
[TBL] [Abstract][Full Text] [Related]
8. Comparison of intravitreal melphalan with and without topotecan in the management of vitreous disease in retinoblastoma.
Kiratli H; Koç I; Öztürk E; Varan A; Akyüz C
Jpn J Ophthalmol; 2020 Jul; 64(4):351-358. PubMed ID: 32447585
[TBL] [Abstract][Full Text] [Related]
9. Low retinal toxicity of intravitreal carboplatin associated with good retinal tumour control in transgenic murine retinoblastoma.
Lemaître S; Poyer F; Fréneaux P; Leboucher S; Doz F; Cassoux N; Thomas CD
Clin Exp Ophthalmol; 2020 May; 48(4):500-511. PubMed ID: 31872542
[TBL] [Abstract][Full Text] [Related]
10. Is intravitreal topotecan toxic to retinal function?
Nadelmann J; Francis JH; Brodie SE; Muca E; Abramson DH
Br J Ophthalmol; 2021 Jul; 105(7):1016-1018. PubMed ID: 32665221
[TBL] [Abstract][Full Text] [Related]
11. INTRAVITREOUS CHEMOTHERAPY FOR ACTIVE VITREOUS SEEDING FROM RETINOBLASTOMA: Outcomes After 192 Consecutive Injections. The 2015 Howard Naquin Lecture.
Shields CL; Douglass AM; Beggache M; Say EA; Shields JA
Retina; 2016 Jun; 36(6):1184-90. PubMed ID: 26630319
[TBL] [Abstract][Full Text] [Related]
12. Retinoblastoma Control With Primary Intra-arterial Chemotherapy: Outcomes Before and During the Intravitreal Chemotherapy Era.
Shields CL; Alset AE; Say EA; Caywood E; Jabbour P; Shields JA
J Pediatr Ophthalmol Strabismus; 2016 Sep; 53(5):275-84. PubMed ID: 27486728
[TBL] [Abstract][Full Text] [Related]
13. TOXICITY AND EFFICACY OF INTRAVITREAL MELPHALAN FOR RETINOBLASTOMA: 25 µg Versus 30 µg.
Liao A; Hsieh T; Francis JH; Lavery JA; Mauguen A; Brodie SE; Abramson DH
Retina; 2021 Jan; 41(1):208-212. PubMed ID: 32106160
[TBL] [Abstract][Full Text] [Related]
14. Intravitreal Lower-Dose (20 µg) Melphalan for Persistent or Recurrent Retinoblastoma Vitreous Seeds.
Tuncer S; Balcı Ö; Tanyıldız B; Kebudi R; Shields CL
Ophthalmic Surg Lasers Imaging Retina; 2015 Oct; 46(9):942-8. PubMed ID: 26469234
[TBL] [Abstract][Full Text] [Related]
15. Ocular and systemic toxicity of intravitreal topotecan in rabbits for potential treatment of retinoblastoma.
Buitrago E; Del Sole MJ; Torbidoni A; Fandino A; Asprea M; Croxatto JO; Chantada GL; Bramuglia GF; Schaiquevich P
Exp Eye Res; 2013 Mar; 108():103-9. PubMed ID: 23333535
[TBL] [Abstract][Full Text] [Related]
16. Addition of intravitreal carboplatin with melphalan for management of vitreous seeding in retinoblastoma.
Riazi-Esfahani H; Masoomian B; Khodabandeh A; Amini A; Taghizadeh S; Boujabadi L; Sharifkashani S; Shields CL; Ghassemi F
Graefes Arch Clin Exp Ophthalmol; 2023 Apr; 261(4):1167-1175. PubMed ID: 36401651
[TBL] [Abstract][Full Text] [Related]
17. Heterochromia following intravitreal chemotherapy in two cases.
Camp DA; Lally SE; Shields CL
J AAPOS; 2019 Aug; 23(4):241-243. PubMed ID: 31039403
[TBL] [Abstract][Full Text] [Related]
18. Rescue intra-arterial chemotherapy following retinoblastoma recurrence after initial intra-arterial chemotherapy.
Shields CL; Say EA; Pointdujour-Lim R; Cao C; Jabbour PM; Shields JA
J Fr Ophtalmol; 2015 Jun; 38(6):542-9. PubMed ID: 25982423
[TBL] [Abstract][Full Text] [Related]
19. Local and systemic toxicity of intravitreal melphalan for vitreous seeding in retinoblastoma: a preclinical and clinical study.
Francis JH; Schaiquevich P; Buitrago E; Del Sole MJ; Zapata G; Croxatto JO; Marr BP; Brodie SE; Berra A; Chantada GL; Abramson DH
Ophthalmology; 2014 Sep; 121(9):1810-7. PubMed ID: 24819859
[TBL] [Abstract][Full Text] [Related]
20. Intravitreal chemotherapy in retinoblastoma: expanded use beyond intravitreal seeds.
Abramson DH; Ji X; Francis JH; Catalanotti F; Brodie SE; Habib L
Br J Ophthalmol; 2019 Apr; 103(4):488-493. PubMed ID: 29875233
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
